Reference

The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in TB drug discovery by breaking down barriers among competing labs and institutions, has reached the 10-year landmark. ... Scientific contributions. Development of a fast-acting, universal drug regimen for TB is hindered by incomplete understanding of TB ...

Similar content being viewed by others Therapeutic host-directed strategies to improve outcome in tuberculosis C. Young, G. Walzl & N. Du Plessis Efficacy of anti-tuberculosis drugs for the treatment of latent tuberculosis infection: a systematic review and network meta-analysis Panida Yoopetch, Thunyarat Anothaisintawee, … Usa Chaikledkaew A broad spectrum anti-bacterial peptide with an adjunct potential for tuberculosis chemotherapy Komal Umashankar Rao, Domhnall Iain Henderson, … Gabriela Godaly Introduction The Nobel Prize-winning discovery of streptomycin has enabled the treatment of several infectious diseases, including tuberculosis (TB). Loss of allosteric regulation in α-isopropylmalate synthase identified as an antimicrobial resistance mechanism npj Antimicrobials and Resistance (2023) Treatments of Mycobacterium tuberculosis and Toxoplasma gondii with Selenium Nanoparticles BioNanoScience (2023) Advertisement Explore content About the journal Publish with us Search Quick links Nature Reviews Microbiology (Nat Rev Microbiol) Advertisement Anti-tuberculosis treatment strategies and drug development: challenges and priorities Nature Reviews Microbiology volume 20, pages 685–701 (2022)Cite this article 35k Accesses 106 Citations 155 Altmetric Metrics details Subjects Abstract Despite two decades of intensified research to understand and cure tuberculosis disease, biological uncertainties remain and hamper progress. first, the inventory of available assays and models that collectively recapitulate micro-environmental conditions encountered in vivo and produce all potentially relevant pathophysiological states of the bacteria, validation of in vitro assay panels that predict clinical treatment shortening, and determination of which animal models are required to bridge in vitro assays and clinical efficacy for new drug candidates; second, the identification of missing assays, models, and bacterial profiles to refine the predictive power of the approach and determination of how they integrate within a patient to drive treatment outcome (that is, the response to treatment may be more complex than the sum of its parts, even if, collectively, assays and models faithfully capture all relevant in vivo conditions). ©ronique A. Dartois Harvard T.H. Chan School of Public Health, Department of Immunology and Infectious Diseases, Boston, MA, USA Eric J. Rubin You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar Contributions V. A. D. researched data for the article.

Frontline tuberculosis (TB) drugs include isoniazid, pyrazinamide, ethambutol, and rifampicin, all developed more than 40 years ago. The rational, mechanism-based development of new TB drugs is urgently needed. History recounts streptomycin and para-aminosalicylic acid (PAS) among the first clinical antibiotics developed.